|
ALS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6805445923751E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.38330491295369E-11 |
| Normal-vs-Stage2 |
6.07920000006423E-07 |
| Normal-vs-Stage3 |
2.30010455126717E-11 |
| Normal-vs-Stage4 |
1.87300175369387E-11 |
| Stage1-vs-Stage2 |
7.617400E-01 |
| Stage1-vs-Stage3 |
1.826170E-01 |
| Stage1-vs-Stage4 |
2.315500E-02 |
| Stage2-vs-Stage3 |
5.398800E-01 |
| Stage2-vs-Stage4 |
2.147400E-01 |
| Stage3-vs-Stage4 |
3.822000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.88022947106492E-13 |
| Normal-vs-AfricanAmerican |
6.34959999999962E-05 |
| Normal-vs-Asian |
3.95609999981339E-07 |
| Caucasian-vs-AfricanAmerican |
6.091200E-01 |
| Caucasian-vs-Asian |
7.819000E-01 |
| AfricanAmerican-vs-Asian |
7.821000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.36349836871364E-11 |
| Normal-vs-Female |
2.12752038208919E-12 |
| Male-vs-Female |
5.603600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.3399997191359E-10 |
| Normal-vs-Age(41-60Yrs) |
6.50879350416744E-12 |
| Normal-vs-Age(61-80Yrs) |
1.93259852565575E-11 |
| Normal-vs-Age(81-100Yrs) |
9.636000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.379800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.823400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.512600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.779800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.072200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.858200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.347900E-02 |
| Classical-VS-Follicular |
4.968000E-01 |
| Classical-VS-Other |
3.479000E-01 |
| Classical-VS-Normal |
1.22030000548889E-08 |
| Tall-VS-Follicular |
3.133200E-01 |
| Tall-VS-Other |
9.582200E-01 |
| Tall-VS-Normal |
4.74240002823478E-09 |
| Follicular-VS-Other |
6.458400E-01 |
| Follicular-VS-Normal |
2.09630000025385E-07 |
| Other-VS-Normal |
1.943870E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.77586850675016E-12 |
| Normal-vs-N1 |
8.85669981798287E-10 |
| N0-vs-N1 |
3.312800E-01 |
|
|
